RU2006127577A - Diazabicyclic aryl derivatives as ligands of nicotinic acetylcholine receptors - Google Patents

Claims (44)

1. Diazabicyclic aryl derivative represented by formula I

, any of its enantiomers or any mixture of its enantiomers, its N-oxide, prodrug or pharmaceutically acceptable addition salt, where n is 1, 2 or 3; and A 'and A "independently from each other represent an aromatic monocyclic and / or polycyclic, carbocyclic and / or heterocyclic group, possibly substituted by one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxyalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkoxyalkoxy, halo, trihaloomethyl, trihaloomethoxy, cyano, nitro, amino, carboxy, amino-carbonyl (carbamoyl) or sulfamoyl or phenyl; a monocyclic or polycyclic, carbocyclic or heterocyclic group, the additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, -alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halogen, trihalomethyl, trihalomethoxy, cyano, nitro, amino, carboxy, am foreign carbonyl (carbamoyl), sulfamoyl and phenyl; and Is a a monocyclic heterocyclic group optionally substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxyalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkoxyalkoxy, , trihalo-methyl, trihalo-methoxy, cyano, nitro, amino, oxo, carboxy, amino-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl-carbonyl-amino sulfamoyl, phenyl or benzyl; or a group of the formula -NR'-B ', -NR' - (C = V) -B 'or -NR' - (C = V) -NR "'- B'; Where R 'represents hydrogen, alkyl or a group of the formula - (C = V) -NR "- B'; R ″ represents hydrogen, alkyl, phenyl or benzyl; V represents O, S or NR ″ ″; where R ″ ″ represents hydrogen, alkyl or cyano; B 'represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, benzyl or a monocyclic heterocyclic group; wherein the phenyl, benzyl, and heterocyclic groups are optionally substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxyalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkoxy alkoxy, halo, trihalo-methyl, trihalo-methoxy, cyano, nitro, amino, oxo, carboxy, amino-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl carbonyl amino, amino carbonyl amino (ureido), N- alkyl-amino-carbonyl-amino (N-alkyl-ureido), N, N-dialkyl-amino-carbonyl-amino (N, N-dialkyl-ureido), sulfamoyl, phenyl and benzyl; and L represents a single (covalent) bond (i.e., L is absent); or a linker group selected from —CH ₂ -, —CH ₂ —CH ₂ -, —CH = CH—, —C≡C—, —Y— (CH ₂ ) _m -, - (CH ₂ ) _m —Y—, -CONR '''' -, -NR '''' CO-, -NR '''' (SO ₂ ) - and - (SO ₂ ) NR '''' -, where Y represents —O—, —S—, —SCH ₂ -, —SO—, —SO ₂ -, —NR ″ ″ -; R ″ ″ ″ represents hydrogen or alkyl; and m is 0, 1, 2 or 3. 2. The diazabicyclic aryl derivative according to claim 1, where n is 1, 2 or 3. 3. The diazabicyclic aryl derivative according to claim 1, where L represents a single (covalent) bond (i.e., L is absent); or a linker group selected from —CH ₂ -, —CH ₂ —CH ₂ -, —CH = CH—, —C≡C—, —Y— (CH ₂ ) _m -, - (CH ₂ ) _m —Y—, -CONR '''' -, -NR '''' CO-, -NR '''' (SO ₂ ) - and - (SO ₂ ) NR '''' -, where Y represents —O—, —S—, —SCH ₂ -, —SO—, —SO ₂ -, —NR ″ ″ -; R ″ ″ ″ represents hydrogen or alkyl; and m is 0, 1, 2 or 3. 4. The diazabicyclic aryl derivative according to claim 3, where L is a single (covalent) bond (that is, L is absent). 5. The diazabicyclic aryl derivative according to claim 1, where A 'represents an aromatic monocyclic or polycyclic, carbocyclic or heterocyclic group optionally substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxy-alkoxy, cycloalkoxy , cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, trihalo-methyl, trihalo-methoxy, cyano, nitro, amino, carboxy, amino-carbonyl (carbamoyl), sulfamoyl and phenyl; or another monocyclic or polycyclic, carbocyclic or heterocyclic group; moreover, an additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkyl -alkyl, cycloalkoxy-alkoxy, halo, trihalomethyl, trihalomethoxy, cyano, nitro, amino, carboxy, amino-carbonyl (carbamoyl), sulfamoyl and phenyl. 6. Diazabicyclic aryl derivative according to claim 5, where A 'represents an aromatic monocyclic heterocyclic group optionally substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxyalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkoxy-alkoxy, halogen, trihalogenomethyl, trihalogenomethoxy, cyano, nitro, amino, carboxy, amino-carbonyl (carbamoyl), sulfamoyl and phenyl. 7. The diazabicyclic aryl derivative according to claim 6, wherein A ′ is a group of furanyl, pyrrolyl, isoxazolyl, 1,3,4-oxadiazolyl, 1,2,3-oxadiazolyl, pyridinyl, pyridazinyl, indolyl, benzofuranyl, benzothienyl, quinoxalinyl or benzimidazolyl. 8. The diazabicyclic aryl derivative of claim 7, wherein A ′ is furan-2,5-diyl. 9. The diazabicyclic aryl derivative according to claim 1, where A ″ is an aromatic monocyclic or polycyclic, carbocyclic or heterocyclic group optionally substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halogen, trihalo-methyl, trihalo-methoxy, cyano, nitro, amino, carboxy, amino-carbonyl (carbamoyl), sulfamoyl and phenyl; or another monocyclic or polycyclic, carbocyclic or heterocyclic group; moreover, an additional monocyclic or polycyclic, carbocyclic or heterocyclic group may optionally be substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkyl -alkyl, cycloalkoxy-alkoxy, halo, trihalomethyl, trihalomethoxy, cyano, nitro, amino, carboxy, amino-carbonyl (carbamoyl), sulfamoyl and phenyl. 10. The diazabicyclic aryl derivative according to claim 9, where A ″ represents a phenyl or naphthyl group, wherein the aryl group is optionally substituted with one or two substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy , cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halogen, trihalo-methyl, trihalo-methoxy, cyano, nitro, amino, carboxy, amino-carbonyl (carbamoyl), sulfamoyl and phenyl. 11. The diazabicyclic aryl derivative of claim 10, wherein A ″ is a phen-1,3-diyl or phen-1,4-diyl group. 12. Diazabicyclic aryl derivative according to claim 1, where B is a monocyclic heterocyclic group optionally substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxy alkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkoxy -alkoxy, halo, trihalo-methyl, trihalo-methoxy, cyano, nitro, amino, oxo, carboxy, amino-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl -carbonyl amino, sulfamoyl, feni la and benzyl. 13. Diazabicyclic aryl derivative according to item 12, where B represents a monocyclic heterocyclic group selected from pyrrolidinyl, pyrrolinyl, pyrrolyl and pyridinyl; wherein the monocyclic heterocyclic group is optionally substituted with one or two substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxy alkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkoxyalkoxy, , trihalo-methyl, cyano, nitro, amino, oxo, carboxy, amino-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl-carbonyl-amino, sulfamoyl and phenyl. 14. Diazabicyclic aryl derivative according to item 13, where B is 3-pyrrolinyl (2,5-dihydro-pyrrolyl) or pyridinyl (pyridin-4-yl), wherein this monocyclic heterocyclic group is optionally substituted with one or two substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl , hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, trihaloomethyl, cyano, nitro, amino, oxo, carboxy, carbamoyl (amino-carbonyl), alkyl-carbamoyl N-alkyl-amino-carbonyl), (N, N-dialkyl-amino-k rbonila) alkyl-carbonyl-amino, sulfamoyl and phenyl. 15. Diazabicyclic aryl derivative according to 14, which represents 5-hydroxy-1- {4- [5- (1-hydroxy-1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) -furan-2-yl] phenyl} -1,5- dihydro-pyrrol-2-one; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} pyrrolidin-2,5-dione N-oxide; or (1,4-diaza-bicyclo [3.2.2] non-4-yl) - [5- (4-pyrrol-1-yl-phenyl) -furan-2-yl] -methanone; or its enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable addition salt thereof. 16. Diazabicyclic aryl derivative according to any one of claims 1 to 11, where B represents a group of the formula -NR'-B ', -NR' - (C = V) -B 'or -NR' - (C = V) -NR '' - B '; Where R 'represents hydrogen, alkyl or a group of the formula - (C = V) -NR "- B'; R ″ represents hydrogen, alkyl, phenyl or benzyl; V represents O, S or NR ″ ″; where R ″ ″ represents hydrogen, alkyl or cyano; and B 'represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, benzyl or a monocyclic heterocyclic group; wherein the phenyl, benzyl, and heterocyclic groups are optionally substituted with one or more substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxyalkyl, alkoxyalkoxy, cycloalkoxy, cycloalkoxyalkyl, cycloalkoxy alkoxy, halo, trihalo-methyl, trihalo-methoxy, cyano, nitro, amino, oxo, carboxy, amino-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl carbonyl amino, amino carbonyl amino (ureido), N- alkyl-amino-carbonyl-amino (N-alkyl-ureido), N, N-dialkyl-amino-carbonyl-amino (N, N-dialkyl-ureido), sulfamoyl, phenyl and benzyl. 17. Diazabicyclic aryl derivative according to clause 16, represented by formula II

any enantiomers thereof or any mixture of its enantiomers, or a prodrug thereof or a pharmaceutically acceptable addition salt, wherein n, A ', A' ', L, R' and B 'are as defined in claim 1. 18. Diazabicyclic aryl derivative according to 17, where L is a single (covalent) bond (i.e., L is absent); R 'represents hydrogen or alkyl; and B 'represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, benzyl or a monocyclic heterocyclic group; moreover, the phenyl, benzyl and heterocyclic groups are optionally substituted with one, two or three substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halogen, trihalogenomethyl, trihalo methoxy, cyano, nitro, amino, oxo, carboxy, amino-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl carbonyl amino, sulfamoyl, phenyl and be Zila. 19. The diazabicyclic aryl derivative according to claim 18, where B 'represents alkyl, phenyl, benzyl, furanyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, imidazolyl, pyrazolyl, pyridinyl, pyrimidinyl or pyridazinyl, the phenyl, benzyl and heterocyclic groups being optionally substituted with one or two substituents, consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, trihalogenomethyl, trihalogenomethoxy, cyano, nitro, amino, oxo, carboxy, amino-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl-carbonyl-amino, sulfamoyl, phenyl and benzyl. 20. The diazabicyclic aryl derivative according to claim 19, where B 'represents alkyl, phenyl, benzyl or pyridinyl, wherein phenyl, benzyl and pyridinyl are optionally substituted with hydroxy, alkoxy, halo, trifluoromethyl, cyano, nitro, amino, N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N dialkyl amino carbonyl, alkyl carbonyl amino, sulfamoyl, phenyl or benzyl. 21. The diazabicyclic aryl derivative according to 17, where n is 2; L is a single (covalent) bond (i.e., L is absent); A 'represents a furanyl, oxazolyl or oxadiazolyl group; A "represents a phenyl group; and R 'represents hydrogen or alkyl; B 'is pyridin-2-yl, pyridin-3-yl, pyridin-4-yl; moreover, pyridinyl may optionally be substituted with one or two substituents, which are alkyl, hydroxy, alkoxy, halo, trihalogenomethyl, trihalogenomethoxy, nitro and / or amino. 22. Diazabicyclic aryl derivative according to item 21, which represents (1,4-diaza-bicyclo [3.2.2] non-4-yl) - {5- [4- (3-nitro-pyridin-2-ylamino) phenyl] furan-2-yl} methanone; or its enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable addition salt thereof. 23. The diazabicyclic aryl derivative according to clause 16, represented by formula III

any enantiomers thereof or any mixture of its enantiomers, or a prodrug thereof or a pharmaceutically acceptable addition salt, wherein n, A ', A' ', L, R', V and B 'are as defined in claim 1. 24. The diazabicyclic aryl derivative of claim 23, wherein L is a single (covalent) bond (i.e., L is absent); R 'represents hydrogen or alkyl; V represents O, S or NR ″ ″; where R ″ ″ represents hydrogen, alkyl or cyano; and B 'represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, benzyl or a monocyclic heterocyclic group, wherein the phenyl, benzyl and heterocyclic groups are optionally substituted with one, two or three substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, trihaloomethyl, trihalogenomethoxy, cyano, nitro, amino, oxo, carboxy, amines o-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl-carbonyl-amino, sulfamoyl, phenyl and benzyl. 25. The diazabicyclic aryl derivative of claim 24, wherein B ′ is phenyl, benzyl or pyridinyl, wherein the phenyl, benzyl and pyridinyl groups are optionally substituted with halo, trifluoromethyl, cyano, nitro, amino, N-alkyl-amino-carbonyl (alkyl- carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl-carbonyl-amino or sulfamoyl. 26. The diazabicyclic aryl derivative according to claim 25, which is N- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} benzamide; N- {3- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} benzamide; N- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -2-nitro-benzamide; N- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) -furan-2-yl] phenyl} -4-nitro-benzamide; N- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3-nitro-benzamide; 4-amino-N- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} benzamide; 3-amino-N- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} benzamide; or N- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} isonicotinamide; or its enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable addition salt thereof. 27. The diazabicyclic aryl derivative according to clause 16, represented by formula IV

any enantiomers thereof or any mixture of its enantiomers, or a prodrug thereof or a pharmaceutically acceptable addition salt, wherein n, A ″, A ″, L, R ′, R ″, V and B ′ are as defined in claim 1. 28. The diazabicyclic aryl derivative of claim 27, wherein L is a single (covalent) bond (ie, L is absent); R 'represents hydrogen, alkyl or a group of the formula - (C = V) -NR "- B'; R ″ represents hydrogen, alkyl, phenyl or benzyl; V represents O, S or NR ″ ″; where R ″ ″ represents hydrogen, alkyl or cyano; and B 'represents hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, phenyl, benzyl or a monocyclic heterocyclic group, wherein the phenyl, benzyl and heterocyclic groups are optionally substituted with one, two or three substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, trihaloomethyl, trihalogenomethoxy, cyano, nitro, amino, oxo, carboxy, amines o-carbonyl (carbamoyl), N-alkyl-amino-carbonyl (alkyl-carbamoyl), N, N-dialkyl-amino-carbonyl, alkyl-carbonyl-amino, amino-carbonyl-amino (ureido), N-alkyl-amino -carbonyl-amino (N-alkyl-ureido), N, N-dialkyl-amino-carbonyl-amino (N, N-dialkyl-ureido), sulfamoyl, phenyl and benzyl. 29. The diazabicyclic aryl derivative of claim 28, wherein B ′ is alkyl, phenyl or benzyl, the phenyl and benzyl groups being optionally substituted with one or two substituents, which are hydroxy, alkoxy, halo, trifluoromethyl, nitro, amino, alkyl-carbonyl -amino, amino-carbonyl-amino (ureido), N-alkyl-amino-carbonyl-amino (N-alkyl-ureido) and / or N, N-dialkyl-amino-carbonyl-amino (N, N-dialkyl-ureido ) 30. Diazabicyclic aryl derivative according to item 27, where n is 2; L is a single (covalent) bond (i.e., L is absent); A 'represents a group of furanyl, oxazolyl, oxadiazolyl, thiazolyl or pyridazinyl; A "represents a phenyl group; and R 'represents hydrogen, alkyl or - (C = O) -NH-B'-; R ″ represents hydrogen, alkyl, phenyl or benzyl; V represents O, S or NH; and B ′ represents a group of the formula —CH ₃ , —CH ₂ CH ₃ , —CH = CH ₂ , —CH = CH — CH = CH ₂ , cyclopenta-1-enyl, cyclopenta-2,4-dienyl, phenyl or benzyl, moreover, phenyl and benzyl may optionally be substituted with one or two substituents, which are alkyl, hydroxy, alkoxy, halogen, trihalogenomethyl, trihalogenomethoxy, cyano, nitro, amino, amino-carbonyl (amido), N-alkyl-amino-carbonyl (N- alkyl amido), N, N-dialkyl-amino-carbonyl (N, N-dialkyl-amido) and / or alkyl-carbonyl-amino. 31. Diazabicyclic aryl derivative according to item 27, where n is 2; L is a single (covalent) bond (i.e., L is absent); A 'represents a group of furanyl, oxazolyl, oxadiazolyl, thiazolyl or pyridazinyl; A "represents a phenyl group; and R 'represents hydrogen, alkyl or - (C = O) -NH-B'-; R ″ represents hydrogen, alkyl, phenyl or benzyl; V represents O, S or NH; and B ′ represents a group of the formula —CH ₃ , —CH ₂ CH ₃ , —CH = CH ₂ , —CH = CH — CH = CH ₂ , cyclopenta-1-enyl, cyclopenta-2,4-dienyl, phenyl or benzyl, moreover, phenyl and benzyl may optionally be substituted with one or two substituents, which are alkyl, hydroxy, alkoxy, halogen, trihalogenomethyl, trihalogenomethoxy, cyano, nitro, amino, amino-carbonyl (amido), N-alkyl-amino-carbonyl (N- alkyl amido), N, N-dialkyl-amino-carbonyl (N, N-dialkyl-amido) and / or alkyl-carbonyl-amino. 32. Diazabicyclic aryl derivative according to p, where B 'represents alkyl, phenyl, benzyl or pyridyl, wherein the phenyl, benzyl and pyridyl groups are optionally substituted with one or two substituents selected from the group consisting of hydroxy, alkoxy, halo, trifluoromethyl, nitro, amino, alkyl-carbonyl-amino, N-alkyl-amino-carbonyl-amino (N-alkyl-ureido), N, N-dialkyl-amino-carbonyl-amino (N, N-dialkyl-ureido) and sulfamoyl. 33. Diazabicyclic aryl derivative according to p, which represents 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3-ethyl-urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3-phenyl-urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (2-nitrophenyl) urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (2-acetylaminophenyl) urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (2-aminophenyl) urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (5-chloro-2-methoxyphenyl) - thiourea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (5-chloro-2-methoxy-phenyl ) urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) -furan-2-yl] phenyl} -3-benzyl-urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -1'-benzylaminocarbonyl-3-benzyl-urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (2-chlorophenyl) urea; 1- {3- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3-phenyl-urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (2-fluorophenyl) urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (3-fluorophenyl) urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (2-trifluoromethylphenyl) urea; 1- [2- (3- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) -furan-2-yl] phenyl} -ureido) phenyl] - 3-ethyl urea; 1- {4- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3- (3-trifluoromethylphenyl) urea; or 1- {3- [5- (1,4-diaza-bicyclo [3.2.2] nonan-4-carbonyl) furan-2-yl] phenyl} -3-ethyl-urea; or its enantiomer or a mixture of its enantiomers, or a pharmaceutically acceptable addition salt thereof. 34. A pharmaceutical composition comprising a therapeutically effective amount of a diazabicyclic aryl derivative according to any one of claims 1 to 33 or a pharmaceutically acceptable addition salt thereof, together with at least one pharmaceutically acceptable carrier or diluent. 35. The use of the diazabicyclic aryl derivative according to any one of claims 1 to 33 or a pharmaceutically acceptable addition salt thereof for the manufacture of a pharmaceutical composition / medicament for treating, preventing or alleviating a disease or disorder or condition in a mammal, including humans, sensitive to modulation of cholinergic receptors. 36. The application of claim 35, wherein said disease, disorder, or condition is related to the central nervous system. 37. The application of clause 36, wherein said disease, disorder or condition is anxiety, cognitive impairment, learning deficits, memory deficits and dysfunctions, Alzheimer's disease, attention deficit disorder, hyperactivity disorder and attention deficit disorder, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Gilles de la Tourette’s disease, depression, manic syndrome, manic depression, schizophrenia, obsessive-compulsive disorder (OCD), panic disorders, eating disorders such as nerve anorexia nervosa, bulimia and obesity, narcolepsy, nociception, AIDS dementia, senile dementia, peripheral neuropathy, autism, dyslexia, tardive dyskinesia, hyperkinesia, epilepsy, bulimia, post-traumatic syndrome, social phobia, sleep disorder, sleep disorders, , late luteal phase syndrome, chronic fatigue syndrome, mutism, trichotillomania and jet lag associated with a change in time zones. 38. The application of claim 35, wherein said disease, disorder, or condition is associated with smooth muscle contractions, including convulsive disorders, angina pectoris, premature birth, convulsions, diarrhea, asthma, epilepsy, tardive dyskinesia, hyperkinesia, premature ejaculation, and erection problems. 39. The application of claim 35, wherein said disease, disorder or condition is related to the endocrine system, such as thyrotoxicosis, pheochromocytoma, hypertension and arrhythmias. 40. The use of claim 35, wherein said disease, disorder or condition is a neurodegenerative disorder, including transient anoxia and induced neurodegeneration. 41. The use of claim 35, wherein said disease, disorder or condition is an inflammatory disorder, including inflammatory skin disorders such as acne and rosacea, Crohn’s disease, inflammatory bowel disease, ulcerative colitis and diarrhea. 42. The application of clause 35, where the specified disease, disorder or condition is a weak, moderate or even severe pain of acute, chronic or recurrent nature, as well as neuropathic pain and pain caused by migraine, postoperative pain, phantom pain, neuropathic pain, chronic headache, central pain, pain associated with diabetic neuropathy, with neuralgia after therapeutic treatment, or with damage to peripheral nerves. 43. The use of claim 35, wherein said disease, disorder, or condition is associated with withdrawal symptoms caused by cessation of the use of addictive substances, including nicotine-containing products such as tobacco, opioids such as heroin, cocaine and morphine, benzodiazepines and benzodiazepine-like medicines and alcohol. 44. A method of treating, preventing, or alleviating a disease or disorder or condition of a living animal organism, including a human, sensitive to modulation of cholinergic receptors, comprising the step of administering to such a living animal organism in need of a therapeutically effective amount of a diazabicyclic aryl derivative according to any one of claims. 1-33.